The Cell Therapy Market Is Expected To Grow 600% By 2033. This Biotech Is Poised To Capitalize.

Over the last decade, cell therapies have attracted a lot of investor attention to biotechs. These groundbreaking treatments use a patient’s own cells to create personalized medicine that not only improves wellness outcomes for people, but it has the ability to transform the health care and pharmaceutical industries.
On this Growth Stories Spotlight, we talk to Vericel CEO Nick Colangelo to get his insights on the cell therapy market, his plans to expand MACI and burn care treatments and why he thinks Vericel has a unique position in the competitive landscape.
New to trading? Check out our daily newsletter! get.investors....
Get more IBD by subscribing to our channel: / @investorsbusinessdaily
Visit our website: www.investors.com
Like us on Facebook: / investorsbusinessdaily
Follow us on Twitter: / ibdinvestors
Follow us on Instagram: / investorsbusinessdaily
Follow us on StockTwits: stocktwits.com...
Follow us on LinkedIn: / investors-business-daily
Follow us on TikTok: / ibdinvestors
Investor’s Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market.
#InvestorsBusinessDaily #IBD

[@pkj6426]

Fascinating! I was scheduled to have knee surgery last year. I did some research and discovered the Maci alternative to traditional knee arthroscopic surgery…
I’m very hopeful that I might be able to utilize this technology to help me versus some old-school methodology.